A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

R. Saunders, Laura; J. Bankovich, Alexander; Anderson, Wade; Aujay, Monette; Bheddah, Sheila; Black, KristenAnn; Desai, Radhika; A. Escarpe, Paul; Hampl, Johannes; Laysang, Amy; Liu, David; Lopez-Molina, Javier; Milton, Milly; Park, Albert; A. Pysz, Marybeth; Shao, Hui; C. Slingerland, Brian; Torgov, Michael; A. Williams, Samuel; Foord, Orit; W. Howard, Philip; Jassem, Jacek; Badzio, A.; Czapiewski, Piotr; H. Harpole, David; Dowlati, Afshin; P. Massion, Pierre; D. Travis, William; Catherine Pietanza, M.; T. Poirier, John; M. Rudin, Charles; Stull, Robert; J. Dylla, Scott

doi:10.1126/scitranslmed.aac9459

Public

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

Published in Science Translational Medicine • Aug 26, 2015

Authors:

Laura R. Saunders

Alexander J. Bankovich

Wade Anderson

Abstract

The high-grade pulmonary neuroendocrine tumors, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC), remain among the most deadly malignancies. Therapies that effectively target and kill tumor-initiating cells (TICs) in these cancers should translate to improved patient sur...

Subject

In vivo

Antibody-drug conjugate

Conjugate

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!